Vaccitech plc – NASDAQ:VACC
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 2 days
Vaccitech stock price monthly change
+47.49%
month
Vaccitech stock price quarterly change
+120.26%
quarter
Vaccitech stock price yearly change
+88.68%
year
Vaccitech key metrics
Market Cap | 192.73M |
Enterprise value | N/A |
P/E | 16.93 |
EV/Sales | -2.70 |
EV/EBITDA | -7.08 |
Price/Sales | 2.30 |
Price/Book | 0.36 |
PEG ratio | -0.09 |
EPS | -2.04 |
Revenue | N/A |
EBITDA | -77.66M |
Income | -77.26M |
Revenue Q/Q | -100% |
Revenue Y/Y | -81.01% |
Profit margin | 29.85% |
Oper. margin | 13.93% |
Gross margin | 0% |
EBIT margin | 13.93% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeVaccitech stock price history
Vaccitech stock forecast
Vaccitech financial statements
| Dec 2022 | 6.45M | -21.16M | -327.75% |
|---|---|---|---|
| Mar 2023 | 468K | -18.22M | -3893.8% |
| Jun 2023 | 334K | -23.80M | -7126.35% |
| Sep 2023 | 0 | -14.07M |
| 2025 | 798.67K | -106M | -13272.06% |
|---|
Analysts Price target
Financials & Ratios estimates
| 2023-03-24 | -0.26 | -0.55 |
|---|---|---|
| 2023-05-12 | -0.58 | -0.48 |
| 2023-08-10 | -0.59 | -0.62 |
| 2023-11-09 | -0.62 | 0.22 |
| Dec 2022 | 270205000 | 27.00M | 9.99% |
|---|---|---|---|
| Mar 2023 | 261816000 | 28.24M | 10.79% |
| Jun 2023 | 246128000 | 28.66M | 11.65% |
| Sep 2023 | 229970000 | 34.36M | 14.94% |
| Dec 2022 | -11.34M | -586K | 484K |
|---|---|---|---|
| Mar 2023 | -3.17M | -2.50M | 1.68M |
| Jun 2023 | -16.95M | -3.02M | 28K |
| Sep 2023 | -11.19M | -36K | 46K |
Vaccitech alternative data
| Aug 2023 | 33 |
|---|---|
| Sep 2023 | 33 |
| Oct 2023 | 33 |
| Nov 2023 | 33 |
| Dec 2023 | 33 |
| Jan 2024 | 33 |
| Feb 2024 | 33 |
| Mar 2024 | 33 |
| Apr 2024 | 33 |
| May 2024 | 33 |
| Jun 2024 | 33 |
| Jul 2024 | 33 |
Vaccitech other data
17.97%
-8.84%
of VACC is owned by hedge funds
6.85M
-3.37M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Aug 2022 | 0 | 69120 |
| Mar 2023 | 0 | 15000 |
| May 2023 | 13750 | 0 |
| Jun 2023 | 10000 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | SCHEEREN JOSEPH director | Ordinary Shares | 10,000 | $2.44 | $24,400 | ||
Purchase | WRIGHT ROBIN director | Ordinary Shares | 13,750 | $2.66 | $36,616 | ||
Sale | ENRIGHT WILLIAM director, officer.. | Ordinary Shares | 15,000 | $2.42 | $36,300 | ||
Option | ELLIS CHRISTOPHER officer: Chief Operating Officer | Share Option (Right to Buy) | 39,176 | N/A | N/A | ||
Sale | ELLIS CHRISTOPHER officer: Chief Operating Officer | Ordinary Shares | 25,000 | $7.07 | $176,700 | ||
Sale | ELLIS CHRISTOPHER officer: Chief Operating Officer | Ordinary Shares | 14,176 | $5.69 | $80,690 | ||
Option | ELLIS CHRISTOPHER officer: Chief Operating Officer | Ordinary Shares | 39,176 | N/A | N/A | ||
Sale | GRIFFITHS GRAHAM officer: Chief Business Officer | Ordinary Shares | 10,000 | $7.39 | $73,870 | ||
Option | ELLIS CHRISTOPHER officer: Chief Operating Officer | Share Option (Right to Buy) | 450 | N/A | N/A | ||
Sale | ELLIS CHRISTOPHER officer: Chief Operating Officer | Ordinary Shares | 450 | $4.78 | $2,152 |
| Insider | Compensation |
|---|---|
| Mr. William J. Enright (1963) Chief Executive Officer & Board Director | $572,880 |
Arbutus: 2 Key Catalysts To Look Forward To After EASL Data Release
Vaccitech: Aiming For A Cure In Chronic Hepatitis B
Arbutus Biopharma; Long-Term Hold With Advancements Into Several Areas Of Interest
Arbutus Biopharma: Recent Acquisition Of Dicerna Makes It An Attractive Investment
Novo Nordisk Enhances Metabolic Disorder Pipeline With RNAi Drug Maker Dicerna
Arrowhead Pharmaceuticals Dives On Safety Issues For ARO-ENaC, But Remains On Track In Other Indications
Vaccitech: The Next Big Vaccine Trade
U.S. IPO Weekly Recap: UFC Owner Endeavor Group Leads A 7 IPO Week
-
When is Vaccitech's next earnings date?
Unfortunately, Vaccitech's (VACC) next earnings date is currently unknown.
-
Does Vaccitech pay dividends?
No, Vaccitech does not pay dividends.
-
How much money does Vaccitech make?
Vaccitech has a market capitalization of 192.73M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 16580.22% to 44.7M US dollars. Vaccitech earned 5.34M US dollars in net income (profit) last year or $0.22 on an earnings per share basis.
-
What is Vaccitech's stock symbol?
Vaccitech plc is traded on the NASDAQ under the ticker symbol "VACC".
-
What is Vaccitech's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Vaccitech?
Shares of Vaccitech can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Vaccitech's key executives?
Vaccitech's management team includes the following people:
- Mr. William J. Enright Chief Executive Officer & Board Director(age: 62, pay: $572,880)
-
How many employees does Vaccitech have?
As Jul 2024, Vaccitech employs 33 workers.
-
When Vaccitech went public?
Vaccitech plc is publicly traded company for more then 4 years since IPO on 30 Apr 2021.
-
What is Vaccitech's official website?
The official website for Vaccitech is vaccitech.co.uk.
-
How can i contact Vaccitech?
Vaccitech can be reached via phone at +44 1865 818808.
Vaccitech company profile:
Vaccitech plc
vaccitech.co.ukExchange:
NASDAQ
Full time employees:
33
Industry:
Biotechnology
Sector:
Healthcare
Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.
The SchrOedinger Building
Oxford, OX4 4GE
Oxford, OX4 4GE
CIK: 0001828185
ISIN: US91864C1071
CUSIP: 91864C107
